Alnylam files its third RNAi drug lumasiran in rare kidney diseaseGene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share XAlnylam files its third RNAi drug lumasiran in rare kidney diseasehttps://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
